{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    8,
    10,
    11,
    13,
    17,
    18,
    19,
    20,
    21,
    23,
    27,
    28,
    29,
    31
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Definition of Terms",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.2",
        "sectionTitle": "Definitions of Terms",
        "description": "Reference for the full definition of stable remission required for maintenance phase entry."
      },
      {
        "id": "ref_2",
        "name": "Safety Extension Study",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1.7",
        "sectionTitle": "Follow-up Phase",
        "description": "Reference to protocol 54135419TRD3008 for potential entry pathways."
      },
      {
        "id": "ref_3",
        "name": "Withdrawal Schedule",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1.6",
        "sectionTitle": "Early Withdrawal/End of Maintenance Phase",
        "description": "Reference to the Time and Events Schedule for withdrawal procedures."
      },
      {
        "id": "ref_4",
        "name": "TRD Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.2.1",
        "sectionTitle": "Study Population",
        "description": "Definition of Treatment-resistant depression added to the synopsis."
      },
      {
        "id": "ref_5",
        "name": "Prohibited Medications",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Attachment 1",
        "sectionTitle": "Prohibited Concomitant Medications",
        "description": "List of medications prohibited during the study period."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Janssen Research & Development is a global organization that operates through different legal entities in various countries.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 1
      },
      {
        "id": "annot_2",
        "text": "The justification for allowing a single excursion of the MADRS total score or one missed MADRS assessment was made on the basis that it could be due to a life event and not the underlying illness.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Protocol Amendments",
        "pageNumber": 7
      },
      {
        "id": "annot_3",
        "text": "Benzodiazepine rescue medication is permitted only post-dose on the dosing day.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Prestudy and Concomitant Therapy",
        "pageNumber": 12
      },
      {
        "id": "annot_4",
        "text": "If the Early Withdrawal Visit is conducted on the same day as a scheduled visit, duplicate assessments are not required.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Time and Events Schedule",
        "pageNumber": 12
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-03-26",
        "description": "Initial release",
        "amendmentNumber": "Original Protocol"
      },
      {
        "id": "ver_2",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-04-21",
        "description": "International Amendment 1",
        "amendmentNumber": "Amendment INT-1"
      },
      {
        "id": "ver_3",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-01-13",
        "description": "Substantial amendment updating safety precautions and eligibility criteria",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "4.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-06-09",
        "description": "Substantial amendment to improve recruitment and revise entry criteria",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_5",
        "versionNumber": "5.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-04-04",
        "description": "Substantial amendment revising stable remission criteria and study stop rules",
        "amendmentNumber": "Amendment 4"
      }
    ],
    "summary": {
      "referenceCount": 5,
      "annotationCount": 4,
      "versionCount": 5
    }
  }
}